cagrilintide novo nordisk Novo's Amylin Injectable Hits 11.8% Weight Reduction in Phase III Trial Novo Nosedives on Underwhelming CagriSema
Description
A 300-pound patient starts at 0.25 mg semaglutide, the same as a 180-pound patient
de Oliveira, S
All findings were reported as efficacy end points, using the data from all the participants who underwent randomization, excluding those who discontinued treatment because of inadvertent enrolment
However, the majority saw no significant improvement in their symptoms, while some respondents even reported that they began to experience louder tinnitus
I reported to cdc
This isnt an attention deficit but rather a difference in attention flexibility and control
